346 related articles for article (PubMed ID: 21041724)
21. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-mediated knockout of six glycosyltransferase genes in Nicotiana benthamiana for the production of recombinant proteins lacking β-1,2-xylose and core α-1,3-fucose.
Jansing J; Sack M; Augustine SM; Fischer R; Bortesi L
Plant Biotechnol J; 2019 Feb; 17(2):350-361. PubMed ID: 29969180
[TBL] [Abstract][Full Text] [Related]
23. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
24. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.
Klein JS; Webster A; Gnanapragasam PN; Galimidi RP; Bjorkman PJ
AIDS; 2010 Jul; 24(11):1633-40. PubMed ID: 20597163
[TBL] [Abstract][Full Text] [Related]
25. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits.
Jin C; Altmann F; Strasser R; Mach L; Schähs M; Kunert R; Rademacher T; Glössl J; Steinkellner H
Glycobiology; 2008 Mar; 18(3):235-41. PubMed ID: 18203810
[TBL] [Abstract][Full Text] [Related]
26. Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.
Wines BD; Trist HM; Esparon S; Impey RE; Mackay GA; Andrews RK; Soares da Costa TP; Pietersz GA; Baker RI; Hogarth PM
Front Immunol; 2021; 12():666813. PubMed ID: 34759915
[TBL] [Abstract][Full Text] [Related]
27. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
[TBL] [Abstract][Full Text] [Related]
28. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
Yang Q; Li C; Wei Y; Huang W; Wang LX
Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
[TBL] [Abstract][Full Text] [Related]
29. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.
Brown EP; Dowell KG; Boesch AW; Normandin E; Mahan AE; Chu T; Barouch DH; Bailey-Kellogg C; Alter G; Ackerman ME
J Immunol Methods; 2017 Apr; 443():33-44. PubMed ID: 28163018
[TBL] [Abstract][Full Text] [Related]
30. Fc receptor-mediated antiviral antibodies.
Forthal DN; Moog C
Curr Opin HIV AIDS; 2009 Sep; 4(5):388-93. PubMed ID: 20048702
[TBL] [Abstract][Full Text] [Related]
31. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
Wolbank S; Kunert R; Stiegler G; Katinger H
J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
[TBL] [Abstract][Full Text] [Related]
32. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
[TBL] [Abstract][Full Text] [Related]
33. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
Luallen RJ; Lin J; Fu H; Cai KK; Agrawal C; Mboudjeka I; Lee FH; Montefiori D; Smith DF; Doms RW; Geng Y
J Virol; 2008 Jul; 82(13):6447-57. PubMed ID: 18434410
[TBL] [Abstract][Full Text] [Related]
34. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain.
Miranda LR; Duval M; Doherty H; Seaman MS; Posner MR; Cavacini LA
J Immunol; 2007 Jun; 178(11):7132-8. PubMed ID: 17513762
[TBL] [Abstract][Full Text] [Related]
35. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
36. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
38. Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody.
Floss DM; Sack M; Arcalis E; Stadlmann J; Quendler H; Rademacher T; Stoger E; Scheller J; Fischer R; Conrad U
Plant Biotechnol J; 2009 Dec; 7(9):899-913. PubMed ID: 19843249
[TBL] [Abstract][Full Text] [Related]
39. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
[TBL] [Abstract][Full Text] [Related]
40. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
